


### CLAIMS

1. A pharmaceutical composition for the treatment of Multiple Sclerosis, other demyelinating conditions and peripheral neuropathy in a mammal, comprising: (a) a compound that exhibits activity, respectively, as an (SRI) anxiolytic agent or an antidepressant, or a pharmaceutically acceptable salt thereof; (b) a neurotransmitter-inducing or precursor agent or pharmaceutically acceptable salt thereof; and (c) a pharmaceutically acceptable carrier; wherein the active agents "a" and "b" above are present in amounts that render the composition effective in treating, respectively, Multiple Sclerosis, other demyelinating conditions, especially encephalomyelitis and peripheral neuropathy, especially painful neuropathy and diabetic neuropathy.

2. A pharmaceutical composition according to claim 1, wherein the (SRI) or pharmaceutically acceptable salt thereof is selected from compounds of the formula I, and their pharmaceutically acceptable salts:



15 wherein phenyl ring A and phenyl ring B can each, independently, be replaced by a naphthyl group, and wherein when phenyl ring A is replaced by a naphthyl group, the ethereal oxygen of structure I and the carbon to which R<sup>3</sup>, R<sup>4</sup> and NR<sup>1</sup>R<sup>2</sup> are attached, are attached to adjacent ring carbon atoms of the naphthyl group and neither of said adjacent ring carbon atoms is also adjacent to a fused ring carbon atom of said naphthyl group;

20 n and m are, selected, independently, from one, two and three;

R<sup>1</sup> and R<sup>2</sup> are selected, independently, from hydrogen (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>4</sub>)alkenyl, and (C<sub>2</sub>-C<sub>4</sub>)alkynyl, or R<sup>1</sup> and R<sup>2</sup>, together with the nitrogen to which they are attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R<sup>1</sup> and R<sup>2</sup> are attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

25 R<sup>3</sup> and R<sup>4</sup> are selected, independently, from hydrogen and (C<sub>1</sub>-C<sub>4</sub>) alkyl optionally substituted with from one to three fluorine atoms, or R<sup>3</sup> and R<sup>4</sup>, together with the carbon to which they are attached, form a four to eight membered saturated carbocyclic ring, and

30

wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

or R<sup>2</sup> and R<sup>3</sup>, together with the nitrogen to which R<sup>2</sup> is attached and the carbon to which R<sup>3</sup> is attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R<sup>2</sup> is attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

each X and each Y is selected, independently, from hydrogen, halo (i.e., chloro, fluoro, bromo or iodo), (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>4</sub>)alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, (C<sub>1</sub>-C<sub>4</sub>)alkylamino, di-[(C<sub>1</sub>-C<sub>4</sub>)alkyl]amino, NR<sup>5</sup>(C=O)(C<sub>1</sub>-C<sub>4</sub>)alkyl wherein R<sup>5</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl, and SO<sub>p</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl wherein p is zero, one or two; and

with the proviso that: (a) no more than one of NR<sup>1</sup>R<sup>2</sup>, CR<sup>3</sup>R<sup>4</sup> and R<sup>2</sup>NCR<sup>3</sup> can form a ring; and (b) at least one X must be other than hydrogen when (i) R<sup>3</sup> and R<sup>4</sup> are both hydrogen, (ii) R<sup>1</sup> and R<sup>2</sup> are selected, independently, from hydrogen and (C<sub>1</sub>-C<sub>4</sub>)alkyl, and (iii) ring B is mono- or disubstituted with, respectively, one or two halo groups;

or a pharmaceutically acceptable salt thereof.

3. A compound or salt according to claim 2, wherein n is one, X is fluoro, R<sup>3</sup> and R<sup>4</sup> are hydrogen, R<sup>1</sup> is hydrogen, R<sup>2</sup> is methyl, m is two and Y is Y<sub>m</sub> is 3,4-dichloro.

4. A compound or salt according to claim 2, wherein m is zero, n is one, R<sup>3</sup> and R<sup>4</sup> are hydrogen, X is chloro, bromo, iodo or methyl, R<sup>1</sup> is hydrogen and R<sup>2</sup> is methyl.

5. A compound or salt according to claim 2, wherein said compound or salt is selected from the following compounds and their pharmaceutically acceptable salts:

- [2-(3,4-Dichlorophenoxy)-5-fluorobenzyl]-dimethylamine;
- [2-(3,4-Dichlorophenoxy)-5-fluorobenzyl]-methylamine;
- [2-(3,4-Dichlorophenoxy)-5-trifluoromethylbenzyl]-dimethylamine;
- N-[4-(3,4-Dichlorophenoxy)-3-dimethylaminomethylphenyl]-acetamide;
- {1-[2-(3,4-Dichlorophenoxy)phenyl]-ethyl}-dimethylamine;
- [2-(3,4-Dichlorophenoxy)-4-trifluoromethylbenzyl]-dimethylamine;
- [2-(3,4-Dichlorophenoxy)-4-trifluoromethylbenzyl]-methylamine;
- [4-Chloro-2-(3,4-dichlorophenoxy)-benzyl]-methylamine;
- {1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;
- {1-[2-(3,4-Dichlorophenoxy)phenyl]-ethyl}-methylamine;
- {1-[2-(4-Chlorophenoxy)phenyl]ethyl}-methylamine;
- [2-(3,4-Dichlorophenoxy)-5-methoxybenzyl]-methylamine;
- [2-(4-Chlorophenoxy)-5-fluorobenzyl]-methylamine;

- {1-[2-(4-Chlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;  
 [2-(3,4-Dichlorophenoxy)-5-methylbenzyl]-dimethylamine;  
 [4-Bromo-2-(3,4-dichlorophenoxy)-benzyl]-methylamine;  
 [5-Bromo-2-(3,4-dichlorophenoxy)-benzyl]-methylamine;  
 5 [2-(3,4-Dichlorophenoxy)-4,5-dimethoxybenzyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-4-methoxybenzyl]-dimethylamine;  
 4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-benzonitrile;  
 [2-(3,4-Dichlorophenoxy)-4,5-dimethylbenzyl]-methylamine;  
 3-(3,4-Dichlorophenoxy)-4-methylaminomethyl-benzonitrile;  
 10 (+)-{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;  
 (-)-{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;  
 [2-(3,4-Dichlorophenoxy)-5-trifluoromethyl-benzyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-4-methoxybenzyl]-methylamine;  
 [2-(4-Chloro-3-fluorophenoxy)-5-fluorobenzyl]-methylamine;  
 15 [2-(3-Chloro-4-fluorophenoxy)-5-fluorobenzyl]-methylamine;  
 (+/-)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine;  
 (-)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine;  
 (+)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine;  
 2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-N-methylpyrrolidine;  
 20 {1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1-methylethyl}-methylamine;  
 {1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1-methylethyl}-dimethylamine;  
 [4-Chloro-2-(4-chlorophenoxy)-5-fluorobenzyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-5-fluoro-4-methoxybenzyl]-methylamine;  
 [4-(3,4-Dichlorophenoxy)-3-(dimethylaminomethyl)-phenyl]-dimethylamine  
 25 [5-Fluoro-2-(4-fluoro-3-methoxyphenoxy)-benzyl]-dimethylamine;  
 [2-(4-Chlorophenoxy)-5-isopropylbenzyl]-methylamine;  
 {1-[2-(4-Chlorophenoxy)-5-trifluoromethylphenyl]-ethyl}-methylamine;  
 [2-(4-Chlorophenoxy)-4,5-dimethylbenzyl]-methylamine;  
 {1-[5-Chloro-2(3,4-dichlorophenoxy)phenyl]-propyl}-methylamine;  
 30 [2-(3,4-Dichlorophenoxy)-5-methylsulfanyl-benzyl]-methylamine;  
 {1-[2-(3,4-Dichlorophenoxy)-5-methylsulfanyl-phenyl]-ethyl}-methylamine;  
 {1-[2-(3,4-Dichloro-phenoxy)-5-methylsulfanyl-phenyl]-1-methylethyl}-methylamine;  
 [2-(3,4-Dichlorophenoxy)-5-methylsulfanyl-benzyl]-dimethylamine;  
 [2-(3,4-Dichlorophenoxy)-5-methanesulfinyl-benzyl]-dimethylamine ;  
 35 [2-(3,4-Dichlorophenoxy)-5-methanesulfinyl-benzyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-5-methanesulfonyl-benzyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-5-methanesulfonyl-benzyl]-dimethylamine;

[2-(3,4-Dichlorophenoxy)-5-(propane-2-sulfonyl)-benzyl]-methylamine;

2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-piperidine;

2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1-methyl-piperidine;

3-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-4-methyl-morpholine;

5 2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1,2-dimethyl-piperidine;

{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-cyclopropyl}-dimethylamine;

2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1,5-dimethyl-pyrrolidine;


3-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-4-methyl-thiomorpholine;

{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-cyclopentyl}-methylamine;

10 {1-[2-(3,4-Dichlorophenoxy)-5-(propane-2-sulfonyl)-phenyl]-ethyl}-methylamine; and

[4-Chloro-2-(3,4-dichlorophenoxy)-5-methanesulfonyl-benzyl]-methylamine.

6. A pharmaceutical composition according to claim 1, wherein the (SRI) antidepressant or anxiolytic agent or pharmaceutically acceptable salt thereof is selected from compounds of the formula II, as defined below, and their pharmaceutically acceptable salts:



15 wherein phenyl ring A and phenyl ring B can each, independently, be replaced by a naphthyl group, and wherein when phenyl ring A is replaced by a naphthyl group, the ethereal oxygen of formula II and the carbon to which R<sup>3</sup>, R<sup>4</sup> and NR<sup>1</sup>R<sup>2</sup> are attached, are attached to adjacent ring carbon atoms of the naphthyl group and neither of said adjacent ring carbon atoms is also adjacent to a fused ring carbon atom of said naphthyl group;

20 n and m are, selected, independently, from one, two and three;

R<sup>1</sup> and R<sup>2</sup> are selected, independently, from hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>4</sub>)alkenyl, and (C<sub>2</sub>-C<sub>4</sub>)alkynyl, or R<sup>1</sup> and R<sup>2</sup>, together with the nitrogen to which they are attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the  
25 nitrogen to which R<sup>1</sup> and R<sup>2</sup> are attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, and wherein said ring may optionally be

substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>3</sup> and R<sup>4</sup> are selected, independently, from hydrogen and (C<sub>1</sub>-C<sub>4</sub>) alkyl optionally substituted with from one to three fluorine atoms, or R<sup>3</sup> and R<sup>4</sup>, together with the carbon to which they are attached, form a four to eight membered saturated carbocyclic ring, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

or R<sup>2</sup> and R<sup>3</sup>, together with the nitrogen to which R<sup>2</sup> is attached and the carbon to which R<sup>3</sup> is attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R<sup>2</sup> is attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

each X is selected, independently, from phenyl, heteroaryl and heterocycle, and wherein each X may be further substituted by hydrogen, halo, (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>4</sub>)alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, hydroxy, carbonyl, (C<sub>1</sub>-C<sub>4</sub>)alkylamino, di-[(C<sub>1</sub>-C<sub>4</sub>)alkyl]amino, NR<sup>5</sup>(C=O)(C<sub>1</sub>-C<sub>4</sub>)alkyl, SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup> and SO<sub>p</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, wherein R<sup>5</sup> and R<sup>6</sup> are selected, independently, from hydrogen and (C<sub>1</sub>-C<sub>6</sub>)alkyl, and p is zero, one or two;

each Y is selected, independently, from hydrogen, halo, (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>4</sub>)alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, (C<sub>1</sub>-C<sub>4</sub>)alkylamino, di-[(C<sub>1</sub>-C<sub>4</sub>)alkyl]amino, NR<sup>5</sup>(C=O)(C<sub>1</sub>-C<sub>4</sub>)alkyl, SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup> and SO<sub>p</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, wherein R<sup>5</sup> and R<sup>6</sup> are selected, independently, from hydrogen and (C<sub>1</sub>-C<sub>6</sub>)alkyl, and p is zero, one or two; and

each Z is selected independently from hydrogen, halo, (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>4</sub>)alkoxy;

or a pharmaceutically acceptable salt thereof.

7. A compound of salt according to claim 6, wherein ring B is phenyl, not replaced with a naphthyl group.

8. A compound or salt according to claim 6, wherein each Y is hydrogen or halo.

9. A compound or salt according to claim 7, wherein m is 1 or 2, and wherein each Y is chlorine.

10. A compound or salt according to claim 6, wherein X is selected from furan, thiophene, pyrrole, and 1,2,3-triazole, and wherein X may be further substituted.

11. A compound or salt according to claim 6, wherein each Z is selected from hydrogen and halo.

12. A compound or salt according to claim 11, wherein each Z is hydrogen.
13. A compound or salt according to claim 6, wherein R<sup>3</sup> and R<sup>4</sup> are independently selected from hydrogen and unsubstituted (C<sub>1</sub>-C<sub>4</sub>) alkyl.
14. A compound or salt according to claim 13, wherein one or both of R<sup>3</sup> and R<sup>4</sup> are hydrogen.
15. A compound or salt according to claim 6, wherein R<sup>1</sup> and R<sup>2</sup> are independently selected from hydrogen and unsubstituted (C<sub>1</sub>-C<sub>4</sub>)alkyl.
16. A compound or salt according to claim 15, wherein one of R<sup>1</sup> and R<sup>2</sup> is hydrogen and the other of R<sup>1</sup> and R<sup>2</sup> is (C<sub>1</sub>-C<sub>4</sub>)alkyl.
17. A compound or salt according to claim 15, wherein one of R<sup>1</sup> and R<sup>2</sup> is hydrogen and the other of R<sup>1</sup> and R<sup>2</sup> is methyl.
18. A compound according to claim 6, selected from the group consisting of:
- [4-(3,4-Dichlorophenoxy)-biphenyl-3-ylmethyl]-methylamine;
- [2-(3,4-Dichlorophenoxy)-5-thiophen-3-ylbenzyl]-methylamine;
- [2-(3,4-Dichlorophenoxy)-4-thiophen-3-ylbenzyl]-methylamine;
- [2-(3,4-Dichlorophenoxy)-4-furan-2-ylbenzyl]-methylamine;
- [2-(3,4-Dichlorophenoxy)-5-furan-2-ylbenzyl]-methylamine;
- N-[4'-(3,4-Dichlorophenoxy)-3'-methylaminomethyl-biphenyl-3-yl]-acetamide;
- [2-(3,4-Dichlorophenoxy)-5-thiophen-2-ylbenzyl]-methylamine;
- [4-(3,4-Dichlorophenoxy)-4'-fluoro-biphenyl-3-ylmethyl]-methyamine;
- [2-(3,4-Dichlorophenoxy)-5-[1,2,3]triazol-1-ylbenzyl]-methylamine;
- [2-(3,4-Dichlorophenoxy)-5-[1,2,3]triazol-2-ylbenzyl]-methylamine;
- [2-(3,4-Dichlorophenoxy)-5-pyridin-2-ylbenzyl]-methylamine;
- [2-(3,4-Dichlorophenoxy)-5-pyridin-3-ylbenzyl]-methylamine;
- 1-[4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-phenyl]-1H-pyrazol-3-ylamine;
- [2-(3,4-Dichlorophenoxy)-5-pyridin-4-ylbenzyl]-methylamine;
- [3-(3,4-Dichlorophenoxy)-biphenyl-4-ylmethyl]-methylamine;
- [4-(3,4-Dichlorophenoxy)-4'-methyl-biphenyl-3-ylmethyl]-methylamine;
- [2-(3,4-Dichlorophenoxy)-4-thiophen-2-ylbenzyl]-methylamine;
- [2-(3,4-Dichlorophenoxy)-5-pyrimidin-2-ylbenzyl]-methylamine;
- [2-(3,4-Dichlorophenoxy)-5-pyrimidin-4-ylbenzyl]-methylamine;
- [2-(3,4-Dichlorophenoxy)-5-(2-methylpyrimidin-4-yl)-benzyl]-methylamine;
- {1-[2-(3,4-Dichlorophenoxy)-5-(2-methylpyrimidin-4-yl)-phenyl]-ethyl}-methylamine;
- 4-[4-(3,4-Dichlorophenoxy)-3-(1-methylpyrrolidin-2-yl)-phenyl]-2-methylpyrimidine;
- [2-(4-Chlorophenoxy)-5-(1-methyl-1H-pyrrol-3-yl)-benzyl]-dimethylamine;
- [5-(1-methyl-1H-pyrrol-3-yl)-2-(naphthalen-2-yloxy)-benzyl]-dimethyl amine;
- [5-Imidazol-1-yl-2-(naphthalen-2-yloxy)-benzyl]-dimethylamine;

- 1,5,5-Trimethyl-3-[3-methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-imidazolidine-2,4-dione;  
1-Methyl-3-[3-methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-imidazolidine-2,4-dione;
- 5 3-[3-Methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-thiazolidine-2,4-dione;  
3-[3-Methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-oxazolidine-2,4-dione;  
3-[3-Methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-oxazolidin-2-one;  
3-[3-Methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-thiazolidin-2-one;  
1-Methyl-3-[3-methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-imidazolidin-2-one;
- 10 1-Methyl-3-[3-methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-tetrahydropyrimidin-2-one;  
1-[4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-phenyl]-3-methyl-tetrahydropyrimidin-2-one;
- 15 1-[4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-phenyl]-3-methylimidazolidin-2-one;  
3-[4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-phenyl]-thiazolidin-2-one;  
3-[4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-phenyl]-oxazolidin-2-one;  
[2-(3,4-Dichlorophenoxy)-5-(2-methylthiazol-4-yl)-benzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-(2-methyloxazol-4-yl)-benzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-(2,5-dimethyloxazol-4-yl)-benzyl]-methylamine;
- 20 [2-(3,4-Dichlorophenoxy)-5-(2,5-dimethylthiazol-4-yl)-benzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-(5-methyl-[1,2,4]thiadiazol-3-yl)-benzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-[1,2,3]oxadiazol-4-yl-benzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-(5-methyl-[1,2,3]thiadiazol-4-yl)-benzyl]-methylamine;
- 25 [2-(3,4-Dichlorophenoxy)-5-(2,4-dimethyloxazol-5-yl)-benzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-(2,4-dimethylthiazol-5-yl)-benzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-[1,2,4]triazol-1-ylbenzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-(3-methyl-[1,2,4]triazol-1-yl)-benzyl]-methylamine;  
[2-(4-Chlorophenoxy)-5-(3,5-dimethyl-[1,2,4]triazol-1-yl)-benzyl]-methylamine;
- 30 [2-(4-Chlorophenoxy)-5-tetrazol-1-ylbenzyl]-methylamine;  
[2-(4-Chlorophenoxy)-5-(5-methyltetrazol-1-yl)-benzyl]-dimethylamine;  
[2-(4-Chlorophenoxy)-5-[1,2,4]triazol-4-ylbenzyl]-dimethylamine;  
[2-(4-Chlorophenoxy)-5-(1-methyl-1H-tetrazol-5-yl)-benzyl]-dimethylamine; and  
{1-[2-(3,4-Dichlorophenoxy)-5-(1-methyl-1H-tetrazol-5-yl)-phenyl]-ethyl}-
- 35 dimethylamine.

19 20. A pharmaceutical composition according to claim 1 wherein the neurotransmitter-inducing or precursor agent or a pharmaceutically acceptable salt thereof is selected from:


- 5 L-phenylalanine;  
L-tyrosine;  
L-tryptophan;  
L-DOPA; and  
tyramine

20 21. A pharmaceutical composition according to claim 1 wherein the amount of the (SRI) anxiolytic agent or antidepressant, or pharmaceutically acceptable salt thereof, in said composition is from about 0.05 mg to about 1500 mg and the amount of the neurotransmitter-inducing or precursor agent or pharmaceutically acceptable salt thereof is from about 100 mg to about 5 g/day.

22 22. A pharmaceutical composition according to claim 21 wherein the amount of the (SRI) anxiolytic agent or antidepressant, or pharmaceutically acceptable salt thereof, in said composition is from about 2.5 mg to about 500 mg and the amount of the neurotransmitter-inducing or precursor agent or pharmaceutically acceptable salt thereof is from about 500 mg to about 2000 mg/day.

23 23. A method of treating Multiple Sclerosis, other demyelinating disorders and peripheral neuropathy in a mammal, comprising administering to said mammal: (a) a compound that exhibits activity as an (SRI) anxiolytic agent or an antidepressant, or a pharmaceutically acceptable salt thereof; and (b) neurotransmitter-inducing or precursor agents or pharmaceutically acceptable salt thereof; wherein the active agents "a" and "b" above are present in amounts that render the combination of the two agents effective in treating Multiple Sclerosis, other demyelinating diseases such as encephalomyelitis and peripheral neuropathy such as diabetic neuropathy and painful neuropathy.

24 24. The method according to claim 23, wherein the (SRI) anxiolytic agent or antidepressant or pharmaceutically acceptable salt thereof is selected from compounds of the formula I,





wherein phenyl ring A and phenyl ring B can each, independently, be replaced by a naphthyl group, and wherein when phenyl ring A is replaced by a naphthyl group, the ethereal oxygen of structure I and the carbon to which R<sup>3</sup>, R<sup>4</sup> and NR<sup>1</sup>R<sup>2</sup> are attached, are attached to adjacent ring carbon atoms of the naphthyl group and neither of said adjacent ring carbon atoms is also adjacent to a fused ring carbon atom of said naphthyl group;

n and m are, selected, independently, from one, two and three;

R<sup>1</sup> and R<sup>2</sup> are selected, independently, from hydrogen (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>4</sub>)alkenyl, and (C<sub>2</sub>-C<sub>4</sub>)alkynyl, or R<sup>1</sup> and R<sup>2</sup>, together with the nitrogen to which they are attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R<sup>1</sup> and R<sup>2</sup> are attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>3</sup> and R<sup>4</sup> are selected, independently, from hydrogen and (C<sub>1</sub>-C<sub>4</sub>) alkyl optionally substituted with from one to three fluorine atoms, or R<sup>3</sup> and R<sup>4</sup>, together with the carbon to which they are attached, form a four to eight membered saturated carbocyclic ring, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;


or R<sup>2</sup> and R<sup>3</sup>, together with the nitrogen to which R<sup>2</sup> is attached and the carbon to which R<sup>3</sup> is attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R<sup>2</sup> is attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

each X and each Y is selected, independently, from hydrogen, halo (i.e., chloro, fluoro, bromo or iodo), (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>4</sub>)alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, (C<sub>1</sub>-C<sub>4</sub>)alkylamino, di-[(C<sub>1</sub>-C<sub>4</sub>)alkyl]amino, NR<sup>5</sup>(C=O)(C<sub>1</sub>-C<sub>4</sub>)alkyl wherein R<sup>5</sup> is hydrogen or (C<sub>1</sub>-C<sub>6</sub>)alkyl, and SO<sub>p</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl wherein p is zero, one or two; and

with the proviso that: (a) no more than one of NR<sup>1</sup>R<sup>2</sup>, CR<sup>3</sup>R<sup>4</sup> and R<sup>2</sup>NCR<sup>3</sup> can form a ring; and (b) at least one X must be other than hydrogen when (i) R<sup>3</sup> and R<sup>4</sup> are both hydrogen, (ii) R<sup>1</sup> and R<sup>2</sup> are selected, independently, from hydrogen and (C<sub>1</sub>-C<sub>4</sub>)alkyl, and (iii) ring B is mono- or disubstituted with, respectively, one or two halo groups;

or a pharmaceutically acceptable salt thereof.

24. The method according to claim 23, wherein the (SRI) anxiolytic agent or antidepressant or pharmaceutically acceptable salt thereof is selected from compounds of the formula II,



wherein phenyl ring A and phenyl ring B can each, independently, be replaced by a naphthyl group, and wherein when phenyl ring A is replaced by a naphthyl group, the ethereal oxygen of structure I and the carbon to which R<sup>3</sup>, R<sup>4</sup> and NR<sup>1</sup>R<sup>2</sup> are attached, are attached to adjacent ring carbon atoms of the naphthyl group and neither of said adjacent ring carbon atoms is also adjacent to a fused ring carbon atom of said naphthyl group;

n and m are, selected, independently, from one, two and three;

R<sup>1</sup> and R<sup>2</sup> are selected, independently, from hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>2</sub>-C<sub>4</sub>)alkenyl, and (C<sub>2</sub>-C<sub>4</sub>)alkynyl, or R<sup>1</sup> and R<sup>2</sup>, together with the nitrogen to which they are attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R<sup>1</sup> and R<sup>2</sup> are attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

R<sup>3</sup> and R<sup>4</sup> are selected, independently, from hydrogen and (C<sub>1</sub>-C<sub>4</sub>) alkyl optionally substituted with from one to three fluorine atoms, or R<sup>3</sup> and R<sup>4</sup>, together with the carbon to which they are attached, form a four to eight membered saturated carbocyclic ring, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

or R<sup>2</sup> and R<sup>3</sup>, together with the nitrogen to which R<sup>2</sup> is attached and the carbon to which R<sup>3</sup> is attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R<sup>2</sup> is attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C<sub>1</sub>-C<sub>6</sub>)alkyl;

each X is selected, independently, from phenyl, heteroaryl and heterocycle, and wherein each X may be further substituted by hydrogen, halo, (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally

substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>4</sub>)alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, hydroxy, carbonyl, (C<sub>1</sub>-C<sub>4</sub>)alkylamino, di-[(C<sub>1</sub>-C<sub>4</sub>)alkyl]amino, NR<sup>5</sup>(C=O)(C<sub>1</sub>-C<sub>4</sub>)alkyl, SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup> and SO<sub>p</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, wherein R<sup>5</sup> and R<sup>6</sup> are selected, independently, from hydrogen and (C<sub>1</sub>-C<sub>6</sub>)alkyl, and p is zero, one or two;

each Y is selected, independently, from hydrogen, halo, (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>4</sub>)alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, (C<sub>1</sub>-C<sub>4</sub>)alkylamino, di-[(C<sub>1</sub>-C<sub>4</sub>)alkyl]amino, NR<sup>5</sup>(C=O)(C<sub>1</sub>-C<sub>4</sub>)alkyl, SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup> and SO<sub>p</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, wherein R<sup>5</sup> and R<sup>6</sup> are selected, independently, from hydrogen and (C<sub>1</sub>-C<sub>6</sub>)alkyl, and p is zero, one or two; and

each Z is selected independently from hydrogen, halo, (C<sub>1</sub>-C<sub>4</sub>)alkyl optionally substituted with from one to three fluorine atoms, (C<sub>1</sub>-C<sub>4</sub>)alkoxy;

or a pharmaceutically acceptable salt thereof.

25 26. The method according to claim 23, wherein the (SRI) antianxiety agent or the (SRI) antidepressant, or pharmaceutically acceptable salt thereof, and the neurotransmitter-inducing or precursor agent or pharmaceutically acceptable salt thereof, are administered as part of the same dosage form.

27. The method according to claim 23, wherein the neurotransmitter-inducing or precursor agent, or pharmaceutically acceptable salt thereof, is administered in an amount from about 100 mg per day to about 5 grams per day, and the (SRI) antianxiety agent or antidepressant, or pharmaceutically acceptable salt thereof, is administered in an amount from about 0.05 mg per day to about 1500 mg per day.

28. The method according to claim 23, wherein the neurotransmitter-inducing or precursor agent is administered in an amount ranging from about 500 mg to about 2000 mg per day and the SRI is administered in an amount ranging from about 2.5 mg per day to 500 mg per day.

29. The method according to claim 23, wherein the neurotransmitter-inducing or precursor agent or pharmaceutically acceptable salt thereof is selected from:

L-phenylalanine;

L-tyrosine;

L-tryptophan;

tyramine; and

L-DOPA

30 31 29 30. The method according to claim 25, wherein the (SRI) antidepressant or anxiolytic agent or pharmaceutically acceptable salt thereof that is employed in such composition is selected from the following compounds and their pharmaceutically acceptable salts:

- [4-(3,4-Dichlorophenoxy)-biphenyl-3-ylmethyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-5-thiophen-3-ylbenzyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-4-thiophen-3-ylbenzyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-4-furan-2-ylbenzyl]-methylamine;  
 5 [2-(3,4-Dichlorophenoxy)-5-furan-2-ylbenzyl]-methylamine;  
 N-[4'-(3,4-Dichlorophenoxy)-3'-methylaminomethyl-biphenyl-3-yl]-acetamide;  
 [2-(3,4-Dichlorophenoxy)-5-thiophen-2-ylbenzyl]-methylamine;  
 [4-(3,4-Dichlorophenoxy)-4'-fluoro-biphenyl-3-ylmethyl]-methyamine;  
 [2-(3,4-Dichlorophenoxy)-5-[1,2,3]triazol-1-ylbenzyl]-methylamine;  
 10 [2-(3,4-Dichlorophenoxy)-5-[1,2,3]triazol-2-ylbenzyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-5-pyridin-2-ylbenzyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-5-pyridin-3-ylbenzyl]-methylamine;  
 1-[4-(3,4-Dichlorophenoxy)-3-methylaminomethylphenyl]-1H-pyrazol-3-ylamine;  
 [2-(3,4-Dichlorophenoxy)-5-pyridin-4-ylbenzyl]-methylamine;  
 15 [3-(3,4-Dichlorophenoxy)-biphenyl-4-ylmethyl]-methylamine;  
 [4-(3,4-Dichlorophenoxy)-4'-methyl-biphenyl-3-ylmethyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-4-thiophen-2-ylbenzyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-5-pyrimidin-2-ylbenzyl]-methylamine;  
 [2-(3,4-Dichlorophenoxy)-5-pyrimidin-4-ylbenzyl]-methylamine;  
 20 [2-(3,4-Dichlorophenoxy)-5-(2-methylpyrimidin-4-yl)-benzyl]-methylamine;  
 {1-[2-(3,4-Dichlorophenoxy)-5-(2-methylpyrimidin-4-yl)-phenyl]-ethyl}-methylamine;  
 4-[4-(3,4-Dichlorophenoxy)-3-(1-methylpyrrolidin-2-yl)-phenyl]-2-methylpyrimidine;  
 [2-(4-Chlorophenoxy)-5-(1-methyl-1H-pyrrol-3-yl)-benzyl]-dimethylamine;  
 [5-(1-methyl-1H-pyrrol-3-yl)-2-(naphthalen-2-yloxy)-benzyl]-dimethyl amine;  
 25 [5-Imidazol-1-yl-2-(naphthalen-2-yloxy)-benzyl]-dimethylamine;  
 1,5,5-Trimethyl-3-[3-methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-  
 imidazolidine-2,4-dione;  
 1-Methyl-3-[3-methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-imidazolidine-2,4-  
 dione;  
 30 3-[3-Methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-thiazolidine-2,4-dione;  
 3-[3-Methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-oxazolidine-2,4-dione;  
 3-[3-Methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-oxazolidin-2-one;  
 3-[3-Methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-thiazolidin-2-one;  
 1-Methyl-3-[3-methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-imidazolidin-2-one;  
 35 1-Methyl-3-[3-methylaminomethyl-4-(naphthalen-2-yloxy)-phenyl]-tetrahydro-  
 pyrimidin-2-one;

1-[4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-phenyl]-3-methyl-tetrahydropyrimidin-2-one;

1-[4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-phenyl]-3-methylimidazolidin-2-one;

3-[4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-phenyl]-thiazolidin-2-one;

5 3-[4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-phenyl]-oxazolidin-2-one;

[2-(3,4-Dichlorophenoxy)-5-(2-methylthiazol-4-yl)-benzyl]-methylamine;

[2-(3,4-Dichlorophenoxy)-5-(2-methyloxazol-4-yl)-benzyl]-methylamine;

[2-(3,4-Dichlorophenoxy)-5-(2,5-dimethyloxazol-4-yl)-benzyl]-methylamine;

[2-(3,4-Dichlorophenoxy)-5-(2,5-dimethylthiazol-4-yl)-benzyl]-methylamine;

10 [2-(3,4-Dichlorophenoxy)-5-(5-methyl-[1,2,4]thiadiazol-3-yl)-benzyl]-methylamine;

[2-(3,4-Dichlorophenoxy)-5-(5-methyl-[1,2,4]oxadiazol-3-yl)-benzyl]-methylamine;

[2-(3,4-Dichlorophenoxy)-5-[1,2,3]oxadiazol-4-yl-benzyl]-methylamine;

[2-(3,4-Dichlorophenoxy)-5-(5-methyl-[1,2,3]thiadiazol-4-yl)-benzyl]-methylamine;

[2-(3,4-Dichlorophenoxy)-5-(2,4-dimethyloxazol-5-yl)-benzyl]-methylamine;

15 [2-(3,4-Dichlorophenoxy)-5-(2,4-dimethylthiazol-5-yl)-benzyl]-methylamine;

[2-(3,4-Dichlorophenoxy)-5-[1,2,4]triazol-1-ylbenzyl]-methylamine;

[2-(3,4-Dichlorophenoxy)-5-(3-methyl-[1,2,4]triazol-1-yl)-benzyl]-methylamine;

[2-(4-Chlorophenoxy)-5-(3,5-dimethyl-[1,2,4]triazol-1-yl)-benzyl]-methylamine;

[2-(4-Chlorophenoxy)-5-tetrazol-1-ylbenzyl]-methylamine;

20 [2-(4-Chlorophenoxy)-5-(5-methyltetrazol-1-yl)-benzyl]-dimethylamine;

[2-(4-Chlorophenoxy)-5-[1,2,4]triazol-4-ylbenzyl]-dimethylamine;

[2-(4-Chlorophenoxy)-5-(1-methyl-1H-tetrazol-5-yl)-benzyl]-dimethylamine; and

{1-[2-(3,4-Dichlorophenoxy)-5-(1-methyl-1H-tetrazol-5-yl)-phenyl]-ethyl}-

dimethylamine.

25 30 31. The method according to claim 24, wherein the (SRI) anxiolytic agent or antidepressant or pharmaceutically acceptable salt thereof that is employed in such method is selected from the following compounds and their pharmaceutically acceptable salts:

[2-(3,4-Dichlorophenoxy)-5-fluorobenzyl]-dimethylamine;

[2-(3,4-Dichlorophenoxy)-5-fluorobenzyl]-methylamine;

30 [2-(3,4-Dichlorophenoxy)-5-trifluoromethylbenzyl]-dimethylamine;

N-[4-(3,4-Dichlorophenoxy)-3-dimethylaminomethylphenyl]-acetamide;

1-[2-(3,4-Dichlorophenoxy)phenyl]-ethyl]-dimethylamine;

[2-(3,4-Dichlorophenoxy)-4-trifluoromethylbenzyl]-dimethylamine;

[2-(3,4-Dichlorophenoxy)-4-trifluoromethylbenzyl]-methylamine;

35 [4-Chloro-2-(3,4-dichlorophenoxy)-benzyl]-methylamine;

{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;

{1-[2-(3,4-Dichlorophenoxy)phenyl]-ethyl}-methylamine;

- {1-[2-(4-Chlorophenoxy)phenyl]ethyl}-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-methoxybenzyl]-methylamine;  
[2-(4-Chlorophenoxy)-5-fluorobenzyl]-methylamine;  
{1-[2-(4-Chlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine.  
5 [2-(3,4-Dichlorophenoxy)-5-methylbenzyl]-dimethylamine;  
[4-Bromo-2-(3,4-dichlorophenoxy)-benzyl]-methylamine;  
[5-Bromo-2-(3,4-dichlorophenoxy)-benzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-4,5-dimethoxybenzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-4-methoxybenzyl]-dimethylamine;  
10 4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-benzonitrile;  
[2-(3,4-Dichlorophenoxy)-4,5-dimethylbenzyl]-methylamine;  
3-(3,4-Dichlorophenoxy)-4-methylaminomethyl-benzonitrile;  
(+)-{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;  
(-)-{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine;  
15 [2-(3,4-Dichlorophenoxy)-5-trifluoromethyl-benzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-4-methoxybenzyl]-methylamine;  
[2-(4-Chloro-3-fluorophenoxy)-5-fluorobenzyl]-methylamine;  
[2-(3-Chloro-4-fluorophenoxy)-5-fluorobenzyl]-methylamine;  
(+/-)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine;  
20 (-)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine;  
(+)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine;  
2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-N-methylpyrrolidine.  
{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1-methylethyl}-methylamine;  
{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1-methylethyl}-dimethylamine;  
25 [4-Chloro-2-(4-chlorophenoxy)-5-fluorobenzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-fluoro-4-methoxybenzyl]-methylamine;  
[4-(3,4-Dichlorophenoxy)-3-(dimethylaminomethyl)-phenyl]-dimethylamine  
[5-Fluoro-2-(4-fluoro-3-methoxyphenoxy)-benzyl]-dimethylamine;  
[2-(4-Chlorophenoxy)-5-isopropylbenzyl]-methylamine;  
30 {1-[2-(4-Chlorophenoxy)-5-trifluoromethylphenyl]-ethyl}-methylamine;  
[2-(4-Chlorophenoxy)-4,5-dimethylbenzyl]-methylamine;  
{1-[5-Chloro-2(3,4-dichlorophenoxy)phenyl]-propyl}-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-methylsulfanyl-benzyl]-methylamine;  
{1-[2-(3,4-Dichlorophenoxy)-5-methylsulfanyl-phenyl]-ethyl}-methylamine;  
35 {1-[2-(3,4-Dichloro-phenoxy)-5-methylsulfanyl-phenyl]-1-methylethyl}-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-methylsulfanyl-benzyl]-dimethylamine;  
[2-(3,4-Dichlorophenoxy)-5-methanesulfinyl-benzyl]-dimethylamine ;

- [2-(3,4-Dichlorophenoxy)-5-methanesulfinyl-benzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-methanesulfonyl-benzyl]-methylamine;  
[2-(3,4-Dichlorophenoxy)-5-methanesulfonyl-benzyl]-dimethylamine;  
[2-(3,4-Dichlorophenoxy)-5-(propane-2-sulfonyl)-benzyl]-methylamine;  
5 2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-piperidine;  
2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1-methyl-piperidine;  
3-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-4-methyl-morpholine;  
2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1,2-dimethyl-piperidine;  
{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-cyclopropyl}-dimethylamine;  
10 2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-1,5-dimethyl-pyrrolidine;  
3-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-4-methyl-thiomorpholine;  
{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-cyclopentyl}-methylamine;  
{1-[2-(3,4-Dichlorophenoxy)-5-(propane-2-sulfonyl)-phenyl]-ethyl}-methylamine; and  
[4-Chloro-2-(3,4-dichlorophenoxy)-5-methanesulfonyl-benzyl]-methylamine.